BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29505604)

  • 1. Hereditary cancer genes are highly susceptible to splicing mutations.
    Rhine CL; Cygan KJ; Soemedi R; Maguire S; Murray MF; Monaghan SF; Fairbrother WG
    PLoS Genet; 2018 Mar; 14(3):e1007231. PubMed ID: 29505604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.
    Piñero TA; Soukarieh O; Rolain M; Alvarez K; López-Köstner F; Torrezan GT; Carraro DM; De Oliveira Nascimento IL; Bomfim TF; Machado-Lopes TMB; Freitas JC; Toralles MB; Sandes KA; Rossi BM; Junior SA; Meira J; Dominguez-Valentin M; Møller P; Vaccaro CA; Martins A; Pavicic WH
    Fam Cancer; 2020 Oct; 19(4):323-336. PubMed ID: 32363481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.
    Pagenstecher C; Wehner M; Friedl W; Rahner N; Aretz S; Friedrichs N; Sengteller M; Henn W; Buettner R; Propping P; Mangold E
    Hum Genet; 2006 Mar; 119(1-2):9-22. PubMed ID: 16341550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.
    Tournier I; Vezain M; Martins A; Charbonnier F; Baert-Desurmont S; Olschwang S; Wang Q; Buisine MP; Soret J; Tazi J; Frébourg T; Tosi M
    Hum Mutat; 2008 Dec; 29(12):1412-24. PubMed ID: 18561205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
    Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
    Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing.
    Auclair J; Busine MP; Navarro C; Ruano E; Montmain G; Desseigne F; Saurin JC; Lasset C; Bonadona V; Giraud S; Puisieux A; Wang Q
    Hum Mutat; 2006 Feb; 27(2):145-54. PubMed ID: 16395668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects.
    Lastella P; Surdo NC; Resta N; Guanti G; Stella A
    BMC Genomics; 2006 Sep; 7():243. PubMed ID: 16995940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
    Sharp A; Pichert G; Lucassen A; Eccles D
    Hum Mutat; 2004 Sep; 24(3):272. PubMed ID: 15300854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
    Thompson BA; Martins A; Spurdle AB
    Clin Genet; 2015 Feb; 87(2):100-8. PubMed ID: 24989436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome.
    Tamura K; Kaneda M; Futagawa M; Takeshita M; Kim S; Nakama M; Kawashita N; Tatsumi-Miyajima J
    Int J Clin Oncol; 2019 Sep; 24(9):999-1011. PubMed ID: 31273487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.
    Ziada-Bouchaar H; Sifi K; Filali T; Hammada T; Satta D; Abadi N
    Fam Cancer; 2017 Jan; 16(1):57-66. PubMed ID: 27468915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.